Bausch + Lomb (NYSE:BLCO) Price Target Raised to $23.00

Posted by George Bondi on Nov 1st, 2026

Bausch + Lomb (NYSE:BLCO – Free Report) had its target price hoisted by Royal Bank Of Canada from $21.00 to $23.00 in a research report report published on Thursday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

BLCO has been the topic of a number of other reports. Needham & Company LLC reissued a “hold” rating on shares of Bausch + Lomb in a research note on Tuesday, September 15th. Evercore set a $17.00 price target on shares of Bausch + Lomb in a research note on Monday, July 6th. Leerink Partners started coverage on shares of Bausch + Lomb in a research report on Wednesday, September 9th. They set an “outperform” rating and a $24.00 price objective on the stock. Citigroup increased their price objective on shares of Bausch + Lomb from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Weiss Ratings upgraded shares of Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bausch + Lomb currently has a consensus rating of “Hold” and an average price target of $20.75.

Read Our Latest Report on BLCO

Bausch + Lomb Stock Performance

Bausch + Lomb stock opened at $19.99 on Thursday. The company has a quick ratio of 1.02, a current ratio of 1.56 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $7.14 billion, a P/E ratio of -64.48, a PEG ratio of 0.59 and a beta of 0.56. The stock’s 50 day moving average is $17.35 and its 200 day moving average is $16.69. Bausch + Lomb has a twelve month low of $14.44 and a twelve month high of $21.36.

Bausch + Lomb (NYSE:BLCO – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.13. The company had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.37 billion. Bausch + Lomb had a positive return on equity of 5.01% and a negative net margin of 2.05%. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter last year, the company earned $0.18 EPS. On average, equities research analysts predict that Bausch + Lomb will post 0.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Bausch + Lomb

In other news, CAO Frederick Munsch sold 52,900 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $16.78, for a total transaction of $887,662.00. Following the transaction, the chief accounting officer directly owned 45,831 shares of the company’s stock, valued at $769,044.18. This represents a 53.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Eschenbach Andrew C. Von sold 12,500 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $16.50, for a total transaction of $206,250.00. Following the transaction, the director owned 69,792 shares in the company, valued at $1,151,568. This represents a 15.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 71,459 shares of company stock valued at $1,194,370 in the last 90 days. Company insiders own 1.45% of the company’s stock.

Hedge Funds Weigh In On Bausch + Lomb

A number of institutional investors and hedge funds have recently made changes to their positions in BLCO. State of Wyoming boosted its stake in shares of Bausch + Lomb by 6.9% during the 3rd quarter. State of Wyoming now owns 13,772 shares of the company’s stock worth $234,000 after acquiring an additional 887 shares during the last quarter. Handelsbanken Fonder AB increased its holdings in Bausch + Lomb by 5.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company’s stock valued at $364,000 after acquiring an additional 1,100 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of Bausch + Lomb by 67.1% during the 1st quarter. Royal Bank of Canada now owns 3,657 shares of the company’s stock worth $58,000 after acquiring an additional 1,468 shares in the last quarter. Roxbury Financial LLC purchased a new position in shares of Bausch + Lomb in the third quarter valued at $33,000. Finally, Squarepoint Ops LLC grew its holdings in shares of Bausch + Lomb by 31.7% in the second quarter. Squarepoint Ops LLC now owns 24,379 shares of the company’s stock valued at $404,000 after purchasing an additional 5,861 shares in the last quarter. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Trending Headlines about Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

Positive Sentiment: Strong quarterly results: Bausch + Lomb reported adjusted earnings of $0.34 per share, well above the $0.21 consensus estimate, while revenue reached approximately $1.38 billion versus expectations of $1.37 billion. Revenue increased 7.3% year over year. Bausch + Lomb Q3 2026 Earnings
Positive Sentiment: Higher 2026 guidance: Management raised its forecast to $5.450 billion-$5.550 billion in revenue and $1.090 billion-$1.140 billion in adjusted EBITDA, citing continued momentum from its Vision ’27 strategy. The improved outlook supports investor confidence in growth and profitability. Bausch + Lomb Raises 2026 Guidance
Positive Sentiment: Analysts raised targets: RBC lifted its price target from $21 to $23 and maintained an “outperform” rating. JPMorgan raised its target from $16 to $22, although it retained a “neutral” rating. The revisions indicate that analysts see improved earnings potential following the results. RBC Raises BLCO Price Target
Neutral Sentiment: Deutsche Bank raised its target from $16 to $20 but kept a “hold” rating, while Wells Fargo increased its target from $18 to $19 and maintained an “equal weight” rating. These calls reflect more cautious views after the stock’s recent advance. Deutsche Bank Adjusts BLCO Price Target

About Bausch + Lomb

(Get Free Report)

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.